Plasma Proteomic Signatures in Alkaptonuria. [PDF]
Finetti R +14 more
europepmc +1 more source
Therapeutic adenine base editor with minimized off-target effects. [PDF]
Sun Y +6 more
europepmc +1 more source
Unveiling the unexpected: refractory rickets as an uncommon presentation of tyrosinemia type I. [PDF]
Ramanna MB, Kamate M, Koppad B.
europepmc +1 more source
Biochemical investigations into the impact of nitisinone treatment on the metabolome and assessment of whether nitisinone induced hypertyrosinaemia alters neurotransmitter metabolism [PDF]
openaire +1 more source
Assessing the risk of cataracts associated with medications: A pharmacovigilance analysis of the FAERS database. [PDF]
Chen H, Hou J, Ouyang L, He G, Huang J.
europepmc +1 more source
Harliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria. [PDF]
Chandani HK +4 more
europepmc +1 more source
Spontaneous Achilles tendon rupture as the initial presentation of ochronosis: a case report. [PDF]
Al-Zagebah A +4 more
europepmc +1 more source
OGFOD1: a critical mediator of chemoresistance in acute myeloid leukemia. [PDF]
Qiu T, Li P, Tan L, Wu S, Luo Q.
europepmc +1 more source
SMILES-based degree molecular descriptors and machine learning for QSPR modeling of anti-alkaptonuria drugs. [PDF]
Wu G, Rasheed MW, Alsulami S.
europepmc +1 more source
Total Knee Arthroplasty in Alkaptonuric Patient With Ochronotic Arthropathy. [PDF]
Michalak P +3 more
europepmc +1 more source

